Italia Grenga
Italia Grenga
National Cancer Institute, NIH
Bestätigte E-Mail-Adresse bei nih.gov
Titel
Zitiert von
Zitiert von
Jahr
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
CR Heery, G O'Sullivan-Coyne, RA Madan, L Cordes, A Rajan, ...
The Lancet Oncology 18 (5), 587-598, 2017
2002017
Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors
J Strauss, CR Heery, J Schlom, RA Madan, L Cao, Z Kang, E Lamping, ...
Clinical Cancer Research 24 (6), 1287-1295, 2018
1472018
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab
V Formica, R Palmirotta, G Del Monte, A Savonarola, G Ludovici, ...
International journal of colorectal disease 26 (2), 143-151, 2011
822011
Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury
CR Heery, BH Singh, M Rauckhorst, JL Marté, RN Donahue, I Grenga, ...
Cancer immunology research 3 (11), 1248-1256, 2015
802015
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
C Jochems, M Fantini, RI Fernando, AR Kwilas, RN Donahue, LM Lepone, ...
Oncotarget 7 (25), 37762, 2016
742016
Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial
CR Heery, NK Ibrahim, PM Arlen, M Mohebtash, JL Murray, K Koenig, ...
JAMA oncology 1 (8), 1087-1095, 2015
622015
Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
RN Donahue, LM Lepone, I Grenga, C Jochems, M Fantini, RA Madan, ...
Journal for immunotherapy of cancer 5 (1), 1-16, 2017
582017
Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines
B Farsaci, RN Donahue, MA Coplin, I Grenga, LM Lepone, AA Molinolo, ...
Cancer immunology research 2 (11), 1090-1102, 2014
502014
Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines
B Farsaci, RN Donahue, MA Coplin, I Grenga, LM Lepone, AA Molinolo, ...
Cancer immunology research 2 (11), 1090-1102, 2014
502014
A fully human IgG1 anti‐PD‐L1 MAb in an in vitro assay enhances antigen‐specific T‐cell responses
I Grenga, RN Donahue, LM Lepone, J Richards, J Schlom
Clinical & translational immunology 5 (5), e83, 2016
422016
Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy
PS Kim, C Jochems, I Grenga, RN Donahue, KY Tsang, JL Gulley, ...
The Journal of Immunology 192 (6), 2622-2633, 2014
422014
Phase I study of a poxviral TRICOM-based vaccine directed against the transcription factor brachyury
CR Heery, C Palena, S McMahon, RN Donahue, LM Lepone, I Grenga, ...
Clinical Cancer Research 23 (22), 6833-6845, 2017
382017
Caregiver distress in the early phases of cancer
R Pellegrino, V Formica, I Portarena, S Mariotti, I Grenga, G Del Monte, ...
Anticancer research 30 (11), 4657-4663, 2010
372010
Role of CA19. 9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients
V Formica, MC Massara, I Portarena, V Fiaschetti, I Grenga, ...
Cancer Biomarkers 5 (4-5), 167-175, 2009
352009
Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial
CR Heery, RA Madan, MN Stein, WM Stadler, RS Di Paola, M Rauckhorst, ...
Oncotarget 7 (42), 69014, 2016
312016
Analyses of 123 peripheral human immune cell subsets: defining differences with age and between healthy donors and cancer patients not detected in analysis of standard immune …
LM Lepone, RN Donahue, I Grenga, S Metenou, J Richards, CR Heery, ...
Journal of circulating biomarkers 5 (Godište 2016), 5-5, 2016
312016
Analyses of pretherapy peripheral immunoscore and response to vaccine therapy
B Farsaci, RN Donahue, I Grenga, LM Lepone, PS Kim, B Dempsey, ...
Cancer immunology research 4 (9), 755-765, 2016
262016
Pharmacokinetic profile and receptor occupancy of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in a phase I, open-label, dose escalation trial in patients with …
CR Heery, GH O'Sullivan Coyne, JL Marte, H Singh, LM Cordes, ...
Journal of Clinical Oncology 33 (15_suppl), 3055-3055, 2015
262015
Rehabilitation in neuro-oncology: a meta-analysis of published data and a mono-institutional experience
V Formica, G Del Monte, I Giacchetti, I Grenga, S Giaquinto, M Fini, ...
Integrative cancer therapies 10 (2), 119-126, 2011
222011
OA18. 03 safety and clinical activity of Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced thymic epithelial tumors (TETs)
A Rajan, C Heery, A Mammen, S Pittaluga, L Lepone, R Donahue, ...
Journal of Thoracic Oncology 12 (1), S314-S315, 2017
212017
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20